Exicure agrees to sell GPC-100 program assets to GPCRT for KRW 6.5 billion
XCUR•Exicure agreed on Nov. 4, 2026, to sell its GPC-100 program assets to GPCRT for KRW 6.5 billion, approximately $4.8 million. GPCRT will pay KRW 2 billion by Nov. 16 and KRW 4 billion at closing, and assume future milestone and royalty obligations.
1. Asset sale terms
Exicure agreed to sell its GPC-100 program assets to GPCRT for KRW 6.5 billion, approximately $4.8 million. GPCRT previously paid KRW 500 million, with KRW 2 billion due Nov. 16, 2026, and KRW 4 billion payable at closing.
2. Costs and closing conditions
At closing, GPCRT will assume future milestone and royalty obligations and bear program costs incurred from Sept. 1, 2026. Exicure will retain other liabilities, including program liabilities incurred before that date, and GPCR USA will remain a wholly owned subsidiary. Closing requires approvals, third-party consents and a waiver from GPCR Therapeutics, including shareholder approval if required.
